@article{UeceylerKewenigKittelSchneideretal.2015, author = {{\"U}{\c{c}}eyler, Nurcan and Kewenig, Susanne and Kittel-Schneider, Sarah and Fallgatter, Andreas J. and Sommer, Claudia}, title = {Increased cortical activation upon painful stimulation in fibromyalgia syndrome}, series = {BMC Neurology}, volume = {15}, journal = {BMC Neurology}, number = {210}, doi = {10.1186/s12883-015-0472-4}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-125230}, year = {2015}, abstract = {Background Fibromyalgia syndrome (FMS) is a chronic condition characterized by widespread pain and associated symptoms. We investigated cerebral activation in FMS patients by functional near-infrared spectroscopy (fNIRS). Methods Two stimulation paradigms were applied: a) painful pressure stimulation at the dorsal forearm; b) verbal fluency test (VFT). We prospectively recruited 25 FMS patients, ten patients with unipolar major depression (MD) without pain, and 35 healthy controls. All patients underwent neurological examination and all subjects were investigated with questionnaires (pain, depression, FMS, empathy). Results FMS patients had lower pressure pain thresholds than patients with MD and controls (p < 0.001) and reported higher pain intensity (p < 0.001). Upon unilateral pressure pain stimulation fNIRS recordings revealed increased bilateral cortical activation in FMS patients compared to controls (p < 0.05). FMS patients also displayed a stronger contralateral activity over the dorsolateral prefrontal cortex in direct comparison to patients with MD (p < 0.05). While all three groups performed equally well in the VFT, a frontal deficit in cortical activation was only found in patients with depression (p < 0.05). Performance and cortical activation correlated negatively in FMS patients (p < 0.05) and positively in patients with MD (p < 0.05). Conclusion Our data give further evidence for altered central nervous processing in patients with FMS and the distinction between FMS and MD.}, language = {en} } @article{VolkertZierhutSchieleetal.2014, author = {Volkert, Julia and Zierhut, Kathrin C. and Schiele, Miriam A. and Wenzel, Martina and Kopf, Juliane and Kittel-Schneider, Sarah and Reif, Andreas}, title = {Predominant polarity in bipolar disorder and validation of the polarity index in a German sample}, doi = {10.1186/s12888-014-0322-8}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-111042}, year = {2014}, abstract = {Background: A large number of patients with bipolar disorder (BD) can be characterized by predominant polarity (PP), which has important implications for relapse prevention. Recently, Popovic et al. (EUR NEUROPSYCHOPHARM 22(5): 339-346, 2012) proposed the Polarity Index (PI) as a helpful tool in the maintenance treatment of BD. As a numeric expression, it reflects the efficacy of drugs used in treatment of BD. In the present retrospective study, we aimed to validate this Index in a large and well characterized German bipolar sample. Methods: We investigated 336 bipolar patients (BP) according to their PP and calculated the PI for each patient in order to prove if maintenance treatment differs according to their PP. Furthermore, we analysed whether PP is associated with demographic and clinical characteristics of BP. Results: In our sample, 63.9\% of patients fulfilled criteria of PP: 169 patients were classified as depressive predominant polarity (DPP), 46 patients as manic predominant polarity (MPP). The two groups differed significantly in their drug regime: Patients with DPP were more often medicated with lamotrigine and antidepressants, patients with MPP were more often treated with lithium, valproate, carbamazepine and first generation antipsychotics. However, patients with DPP and MPP did not differ significantly with respect to the PI, although they received evidence-based and guideline-driven treatment. Conclusion: The reason for this negative finding might well be that for several drugs, which were used frequently, no PI value is available. Nevertheless we suggest PP as an important concept in the planning of BD maintenance treatment.}, language = {en} } @article{UeceylerKewenigKafkeetal.2014, author = {{\"U}{\c{c}}eyler, Nurcan and Kewenig, Susanne and Kafke, Waldemar and Kittel-Schneider, Sarah and Sommer, Claudia}, title = {Skin cytokine expression in patients with fibromyalgia syndrome is not different from controls}, doi = {10.1186/s12883-014-0185-0}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-110624}, year = {2014}, abstract = {Background Fibromyalgia syndrome (FMS) is a chronic pain syndrome of unknown etiology. There is increasing evidence for small nerve fiber impairment in a subgroup of patients with FMS. We investigated whether skin cytokine and delta opioid receptor (DOR) gene expression in FMS patients differs from controls as one potential contributor to small nerve fiber sensitization. Methods We investigated skin punch biopsies of 25 FMS patients, ten patients with monopolar depression but no pain, and 35 healthy controls. Biopsies were obtained from the lateral upper thigh and lower calf. Gene expression of the pro-inflammatory cytokines tumor necrosis factor-alpha (TNF), interleukin (IL)-6, and IL-8 and of the anti-inflammatory cytokine IL-10 was analyzed using quantitative real-time PCR and normalizing data to 18sRNA as housekeeping gene. Additionally, we assessed DOR gene expression. Results All cytokines and DOR were detectable in skin samples of FMS patients, patients with depression, and healthy controls without intergroup difference. Also, gene expression was not different in skin of the upper and lower leg within and between the groups and in FMS patient subgroups. Conclusions Skin cytokine and DOR gene expression does not differ between patients with FMS and controls. Our results do not support a role of the investigated cytokines in sensitization of peripheral nerve fibers as a potential mechanism of small fiber pathology in FMS.}, language = {en} } @article{ManchiaAdliAkulaetal.2013, author = {Manchia, Mirko and Adli, Mazda and Akula, Nirmala and Arda, Raffaella and Aubry, Jean-Michel and Backlund, Lena and Banzato, Claudio E. M. and Baune, Bernhard T. and Bellivier, Frank and Bengesser, Susanne and Biernacka, Joanna M. and Brichant-Petitjean, Clara and Bui, Elise and Calkin, Cynthia V. and Cheng, Andrew Tai Ann and Chillotti, Caterina and Cichon, Sven and Clark, Scott and Czerski, Piotr M. and Dantas, Clarissa and Del Zompo, Maria and DePaulo, J. Raymond and Detera-Wadleigh, Sevilla D. and Etain, Bruno and Falkai, Peter and Fris{\´e}n, Louise and Frye, Mark A. and Fullerton, Jan and Gard, S{\´e}bastien and Garnham, Julie and Goes, Fernando S. and Grof, Paul and Gruber, Oliver and Hashimoto, Ryota and Hauser, Joanna and Heilbronner, Urs and Hoban, Rebecca and Hou, Liping and Jamain, St{\´e}phane and Kahn, Jean-Pierre and Kassem, Layla and Kato, Tadafumi and Kelsoe, John R. and Kittel-Schneider, Sarah and Kliwicki, Sebastian and Kuo, Po-Hsiu and Kusumi, Ichiro and Laje, Gonzalo and Lavebratt, Catharina and Leboyer, Marion and Leckband, Susan G. and L{\´o}pez Jaramillo, Carlos A. and Maj, Mario and Malafosse, Alain and Martinsson, Lina and Masui, Takuya and Mitchell, Philip B. and Mondimore, Frank and Monteleone, Palmiero and Nallet, Audrey and Neuner, Maria and Nov{\´a}k, Tom{\´a}s and O'Donovan, Claire and {\"O}sby, Urban and Ozaki, Norio and Perlis, Roy H. and Pfennig, Andrea and Potash, James B. and Reich-Erkelenz, Daniela and Reif, Andreas and Reininghaus, Eva and Richardson, Sara and Rouleau, Guy A. and Rybakowski, Janusz K. and Schalling, Martin and Schofield, Peter R. and Schubert, Oliver K. and Schweizer, Barbara and Seem{\"u}ller, Florian and Grigoroiu-Serbanescu, Maria and Severino, Giovanni and Seymour, Lisa R. and Slaney, Claire and Smoller, Jordan W. and Squassina, Alessio and Stamm, Thomas and Steele, Jo and Stopkova, Pavla and Tighe, Sarah K. and Tortorella, Alfonso and Turecki, Gustavo and Wray, Naomi R. and Wright, Adam and Zandi, Peter P. and Zilles, David and Bauer, Michael and Rietschel, Marcella and McMahon, Francis J. and Schulze, Thomas G. and Alda, Martin}, title = {Assessment of Response to Lithium Maintenance Treatment in Bipolar Disorder: A Consortium on Lithium Genetics (ConLiGen) Report}, series = {PLoS ONE}, volume = {8}, journal = {PLoS ONE}, number = {6}, doi = {10.1371/journal.pone.0065636}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-130938}, pages = {e65636}, year = {2013}, abstract = {Objective: The assessment of response to lithium maintenance treatment in bipolar disorder (BD) is complicated by variable length of treatment, unpredictable clinical course, and often inconsistent compliance. Prospective and retrospective methods of assessment of lithium response have been proposed in the literature. In this study we report the key phenotypic measures of the "Retrospective Criteria of Long-Term Treatment Response in Research Subjects with Bipolar Disorder" scale currently used in the Consortium on Lithium Genetics (ConLiGen) study. Materials and Methods: Twenty-nine ConLiGen sites took part in a two-stage case-vignette rating procedure to examine inter-rater agreement [Kappa (\(\kappa\))] and reliability [intra-class correlation coefficient (ICC)] of lithium response. Annotated first-round vignettes and rating guidelines were circulated to expert research clinicians for training purposes between the two stages. Further, we analyzed the distributional properties of the treatment response scores available for 1,308 patients using mixture modeling. Results: Substantial and moderate agreement was shown across sites in the first and second sets of vignettes (\(\kappa\) = 0.66 and \(\kappa\) = 0.54, respectively), without significant improvement from training. However, definition of response using the A score as a quantitative trait and selecting cases with B criteria of 4 or less showed an improvement between the two stages (\(ICC_1 = 0.71\) and \(ICC_2 = 0.75\), respectively). Mixture modeling of score distribution indicated three subpopulations (full responders, partial responders, non responders). Conclusions: We identified two definitions of lithium response, one dichotomous and the other continuous, with moderate to substantial inter-rater agreement and reliability. Accurate phenotypic measurement of lithium response is crucial for the ongoing ConLiGen pharmacogenomic study.}, language = {en} } @article{KittelSchneiderKenisScheketal.2012, author = {Kittel-Schneider, Sarah and Kenis, Gunter and Schek, Julia and van den Hove, Daniel and Prickaerts, Jos and Lesch, Klaus-Peter and Steinbusch, Harry and Reif, Andreas}, title = {Expression of monoamine transporters, nitric oxide synthase 3, and neurotrophin genes in antidepressant-stimulated astrocytes}, series = {Frontiers in Psychiatry}, volume = {3}, journal = {Frontiers in Psychiatry}, doi = {10.3389/fpsyt.2012.00033}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-123627}, pages = {33}, year = {2012}, abstract = {Background: There is increasing evidence that glial cells play a role in the pathomechanisms of mood disorders and the mode of action of antidepressant drugs. Methods: To examine whether there is a direct effect on the expression of different genes encoding proteins that have been implicated in the pathophysiology of affective disorders, primary astrocyte cell cultures from rats were treated with two different antidepressant drugs, imipramine and escitalopram, and the RNA expression of brain-derived neurotrophic factor (Bdnf), serotonin transporter (5Htt), dopamine transporter (Dat), and endothelial nitric oxide synthase (Nos3) was examined. Results: Stimulation of astroglial cell culture with imipramine, a tricyclic antidepressant, led to a significant increase of the Bdnf RNA level whereas treatment with escitalopram did not. In contrast, 5Htt was not differentially expressed after antidepressant treatment. Finally, neither Dat nor Nos3 RNA expression was detected in cultured astrocytes. Conclusion: These data provide further evidence for a role of astroglial cells in the molecular mechanisms of action of antidepressants.}, language = {en} } @article{GalimbertiDell'OssoFenoglioetal.2012, author = {Galimberti, Daniela and Dell'Osso, Bernardo and Fenoglio, Chiara and Villa, Chiara and Cortini, Francesca and Serpente, Maria and Kittel-Schneider, Sarah and Weigl, Johannes and Neuner, Maria and Volkert, Juliane and Leonhard, C. and Olmes, David G. and Kopf, Juliane and Cantoni, Claudia and Ridolfi, Elisa and Palazzo, Carlotta and Ghezzi, Laura and Bresolin, Nereo and Altamura, A.C. and Scarpini, Elio and Reif, Andreas}, title = {Progranulin Gene Variability and Plasma Levels in Bipolar Disorder and Schizophrenia}, series = {PLoS One}, volume = {7}, journal = {PLoS One}, number = {4}, doi = {10.1371/journal.pone.0032164}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-131910}, pages = {e32164}, year = {2012}, abstract = {Basing on the assumption that frontotemporal lobar degeneration (FTLD), schizophrenia and bipolar disorder (BPD) might share common aetiological mechanisms, we analyzed genetic variation in the FTLD risk gene progranulin (GRN) in a German population of patients with schizophrenia (n=271) or BPD (n=237) as compared with 574 age-, gender-and ethnicity-matched controls. Furthermore, we measured plasma progranulin levels in 26 German BPD patients as well as in 61 Italian BPD patients and 29 matched controls. A significantly decreased allelic frequency of the minor versus the wild-type allele was observed for rs2879096 (23.2 versus 34.2\%, P<0.001, OR: 0.63, 95\% CI: 0.49-0.80), rs4792938 (30.7 versus 39.7\%, P=0.005, OR: 0.70, 95\% CI: 0.55-0.89) and rs5848 (30.3 versus 36.8, P=0.007, OR: 0.71, 95\% CI: 0.56-0.91). Mean +/- SEM progranulin plasma levels were significantly decreased in BPD patients, either Germans or Italians, as compared with controls (89.69 +/- 3.97 and 116.14 +/- 5.80 ng/ml, respectively, versus 180.81 +/- 18.39 ng/ml P<0.001) and were not correlated with age. In conclusion, GRN variability decreases the risk to develop BPD and schizophrenia, and progranulin plasma levels are significantly lower in BPD patients than in controls. Nevertheless, a larger replication analysis would be needed to confirm these preliminary results.}, language = {en} } @phdthesis{KittelSchneider2010, author = {Kittel-Schneider, Sarah}, title = {Expressionsanalytische und behaviourale Ph{\"a}notypisierung der Nos1 Knockdown Maus}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-52689}, school = {Universit{\"a}t W{\"u}rzburg}, year = {2010}, abstract = {Der gasf{\"o}rmige Neurotransmitter Stickstoffmonoxid (NO) spielt eine Rolle bei verschiedenen physiologischen Vorg{\"a}ngen, aber auch psychiatrischen Erkrankungen wie Aggression, {\"A}ngstlichkeit, Depression und auch bei kognitiven Funktionen. Um mehr {\"u}ber die physiologische Rolle von NO herauszufinden untersuchten wir mittels Gen-Expressionsanalyse und Verhaltensversuchen M{\"a}use, bei denen die neuronale Isoform der Stickstoffmonoxidsynthase ausgeschaltet wurde. Die so genannte NOS-I ist die haupts{\"a}chliche Quelle von NO im zentralen Nervensystem. Knockout Tiere sind wertvolle Werkzeuge um sowohl den Einfluss eines Gens auf Verhalten als auch m{\"o}glicherweise damit zusammenh{\"a}ngende Ver{\"a}nderungen des Transkriptoms zu identifizieren. Dies ist wichtig um herauszufinden, mit welchen molekularen Pfaden bestimmte Verhaltensweisen korreliert sind. In Bezug auf NOS-I gibt es zwei bisher beschriebene Knockout M{\"a}use St{\"a}mme. Es existieren KOex6 Knockout M{\"a}use, in welchen es {\"u}berhaupt keine katalytisch aktive NOS-I gibt und es gibt einen Mausstamm, bei dem Exon 1 deletiert wurde, was aufgrund alternativer NOS-I Splicevarianten zu einer residualen Expression von bis zu 7\% f{\"u}hrt. Daher sind diese M{\"a}sue besser zutreffend als Knockdown M{\"a}use zu bezeichnen. In der vorliegenden Arbeit untersuchten wir die Nos1 Knockdown M{\"a}use, da die hier vorliegende Situation wohl {\"a}hnlicher zu der bei menschlicher genetischer Varianten ist, da eine komplette Disruption bisher noch nicht beim Menschen beschrieben wurde. Es gibt diverse Studien, welche den behaviouralen Ph{\"a}notyp der Nos1 Knockdown M{\"a}use untersuchen, aber diese widersprechen sich zum Teil. Bei unserer Untersuchung legten wir den Schwerpunkt auf Verhaltenstests, welche spezifische Symptome des Aufmerksamkeitsdefizit-/Hyperaktivit{\"a}tssyndrom (ADHS) aufdecken sollten. Wir f{\"u}hrten den Elevated Plus Maze Test (EPM) und ein modifiziertes Lochbrett-Paradigma, die COGITAT-Box, durch. Um die den gefundenen Verhaltens{\"a}nderungen zugrunde liegenden molekularen Mechanismen herauszufinden, suchten wir nach Unterschieden der Expression des Serotonin- (5HTT) und des Dopamintransporters (DAT) zwischen den Knockdown und den Wildtyp M{\"a}usen. Wir hatten spekuliert, dass die Disruption der NOS-I zu einer modifizierten Expression des DAT oder des 5HTT gef{\"u}hrt habe k{\"o}nnte wegen den bekannten engen Interaktionen zwischen dem nitrinergen und den monoaminergen Systemen. Wir fanden einen diskret anxiolytischen Ph{\"a}notyp, da die Knockdown M{\"a}use eine l{\"a}ngere Zeit auf dem offenen Arm des EPM verbrachten bzw. h{\"a}ufiger den offenen Arm betraten im Vergleich zu dem Wildtypen. Dies war nicht durch eine h{\"o}here lokomotorische Aktivit{\"a}t zu erkl{\"a}ren. Auch beobachteten wir ein geschlechterunabh{\"a}ngiges kognitives Defizit im Arbeits- und Referenzged{\"a}chtnis in der COGITAT-Box. {\"U}berraschenderweise fanden wir keine signifikante Dysregulation der Monoamin-Transporter in der Expressionsanalyse mittels der quantitativen Real Time PCR. Dies war eher unerwartet, da vorherige Studien verschiedene Ver{\"a}nderungen im serotonergen und dopaminergen System bei den Nos1 Knockdown M{\"a}usen gefunden hatten, wie z.B. einen verminderten Serotonin-Umsatz in frontalen Cortex und hypofunktionale 5 HT1A and 5HT1B Rezeptoren. Auch ist bekannt, dass NO direkt Monoamin-Transporter nitrosyliert. Zusammenfassend zeigen die Nos1 Knockdown M{\"a}use ein charakteristisches behaviourales Profil mit reduzierter {\"A}ngstlichkeit und Defiziten im Ged{\"a}chtnis. Weitere Studien sollten folgen um zu kl{\"a}ren, ob diese M{\"a}use als Tiermodell f{\"u}r z.B. die Alzheimer-Erkrankung oder das Aufmerksamkeitsdefizit-/Hyperaktivit{\"a}tssyndrom dienen k{\"o}nnten und die weitere pathophysiologische Rolle des NO bei neuropsychiatrischen Erkrankungen herauszufinden.}, subject = {Aufmerksamkeits-Defizit-Syndrom}, language = {de} } @article{RiveroReifSanjuanetal.2010, author = {Rivero, Olga and Reif, Andreas and Sanjuan, Julio and Molto, Maria D. and Kittel-Schneider, Sarah and Najera, Carmen and Toepner, Theresia and Lesch, Klaus-Peter}, title = {Impact of the AHI1 Gene on the Vulnerability to Schizophrenia: A Case-Control Association Study}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-68501}, year = {2010}, abstract = {Background: The Abelson helper integration-1 (AHI1) gene is required for both cerebellar and cortical development in humans. While the accelerated evolution of AHI1 in the human lineage indicates a role in cognitive (dys)function, a linkage scan in large pedigrees identified AHI1 as a positional candidate for schizophrenia. To further investigate the contribution of AHI1 to the susceptibility of schizophrenia, we evaluated the effect of AHI1 variation on the vulnerability to psychosis in two samples from Spain and Germany. Methodology/Principal Findings: 29 single-nucleotide polymorphisms (SNPs) located in a genomic region including the AHI1 gene were genotyped in two samples from Spain (280 patients with psychotic disorders; 348 controls) and Germany (247 patients with schizophrenic disorders; 360 controls). Allelic, genotypic and haplotype frequencies were compared between cases and controls in both samples separately, as well as in the combined sample. The effect of genotype on several psychopathological measures (BPRS, KGV, PANSS) assessed in a Spanish subsample was also evaluated. We found several significant associations in the Spanish sample. Particularly, rs7750586 and rs911507, both located upstream of the AHI1 coding region, were found to be associated with schizophrenia in the analysis of genotypic (p = 0.0033, and 0.031,respectively) and allelic frequencies (p = 0.001 in both cases). Moreover, several other risk and protective haplotypes were detected (0.006,p,0.036). Joint analysis also supported the association of rs7750586 and rs911507 with the risk for schizophrenia. The analysis of clinical measures also revealed an effect on symptom severity (minimum P value = 0.0037). Conclusions/Significance: Our data support, in agreement with previous reports, an effect of AHI1 variation on the susceptibility to schizophrenia in central and southern European populations.}, subject = {Schizophrenie}, language = {en} }